2024 Revenues ($USD) : $52.45B

Switzerland-based Roche Group (OTCMKTS: RHHBY) reported total Group sales of CHF 60.5 billion for fiscal year 2024, representing a 7% increase at constant exchange rates (CER). Excluding diminishing COVID-19 contributions, the underlying base business across both Pharmaceuticals and Diagnostics demonstrated robust growth of 9% (CER).

The Pharmaceuticals Division itself saw sales climb 8% (CER) to CHF 46.2 billion (approx. $52.45 billion based on provided CSV data), fueled by key assets including Vabysmo (ophthalmology), Phesgo (breast cancer), Ocrevus (multiple sclerosis), and Hemlibra (haemophilia A). These four products collectively generated CHF 16.9 billion in sales, an increase of CHF 3.3 billion (CER) over 2023. Headquartered in Basel, Switzerland, Roche's Pharma division employed approximately 41,727 people, while the Group held total assets of $115.55 billion.

Roche maintained significant investment in innovation, with Group Core R&D spend at CHF 13.0 billion (approx. $14.8 billion per CSV). The Pharmaceuticals Division's specific R&D expenditure was CHF 11.1 billion (approx. $12.6 billion, using implied conversion from revenue), equating to roughly 24% of Pharma sales.

On the pipeline and strategic front, notable developments include:

Alzheimer's Disease: Planned presentations on therapeutic and diagnostic programs at the AD/PD 2025 conference (held late March/early April 2025).

Multiple Sclerosis: Anticipated results from the Phase 3 high-dose OCREVUS study in relapsing MS.

Obesity Collaboration: An exclusive collaboration and license agreement inked with Zealand Pharma in March 2025 for the co-development and co-commercialization of petrelintide, potentially combined with Roche's own asset CT-388. Roche paid $1.4 billion upfront as part of a deal worth up to $5.3 billion.

US Research Expansion: The launch of the Roche Genentech Innovation Center Boston at Harvard's Enterprise Research Campus, announced in March 2025, establishing a hub focused on Cardiovascular, Renal, and Metabolism (CVRM) research, AI, and data science.

CEO Thomas Schinecker reiterated Roche's strategic focus on oncology, cardiovascular-metabolic diseases, and neurological disorders, anticipating these areas will represent the dominant global disease burden by 2035. For fiscal year 2025, Roche guided for Group sales growth in the mid-single-digit range (CER) and Core EPS growth in the high-single-digit range (CER).